EPH21 Real-World Evidence of Adverse Kidney Outcomes for Intravitreal Use of Vascular Endothelial Growth Factor (VEGF) Inhibitors Among Patients with Diabetic Retinopathy
- Resource Type
- Abstract
- Source
- In
Value in Health July 2022 25(7) Supplement:S438-S438 - Subject
- Language
- ISSN
- 1098-3015